ArticleClinical and experimental medicine2025
Identification and construction of a novel NET-related gene signature for predicting prognosis in multiple myeloma.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correlation analysis of serum CCL3, TRACP-5b, and sclerostin with the prognosis of multiple myeloma patients.Journal of medical biochemistry · 2026Article
- Longitudinal profiling of serum ADAM17 across clinical stages in multiple myeloma: a dynamic biomarker and its association with T cell alterations.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neutrophil extracellular traps are essential in the development and advancement of multiple myeloma (MM). However, research investigating the prognostic value with NET-related genes (NRGs) in MM has been limited. Patient transcriptomic and clinical information was sourced from the gene expression omnibus database. Cox regression analysis with a univariate approach was employed to explore the link between NRGs and overall survival (OS). Kaplan-Meier methods were applied to assess variations in survival rates. A nomogram integrating clinical data and predictive risk metrics was crafted using multivariate logistic and Cox proportional risk model regression analyses. Additionally, we investigated the disparities in biological pathways, drug sensitivity, and immune cell involvement, and validated differential levels of two key genes through qPCR. We identified 148 differentially expressed NRGs through published articles, of which 14 were associated with prognosis in MM. Least absolute shrinkage and selection operator Cox regression model established a nine-gene NRG signature-comprising ANXA1, ANXA2, ENO1, HIF1A, HSPE1, LYZ, MCOLN3, THBD, and FN1-that demonstrated strong predictive power for patient survival. The Cox regression model with multiple variables demonstrated that the risk score independently predicted OS, showing that those with a high score had worse survival rates. Furthermore, a nomogram incorporating patient age, LDH levels, the International Staging System, and NRGs was developed, demonstrating strong prognostic prediction capabilities. Drug sensitivity correlation analysis also offered valuable guidance for future immuno-oncological therapies and drug selection in MM patients. The NRGs signature was a reliable biomarker for MM, effectively identifying high-risk patients and forecasting clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.